ICAHN School of Medicine At Mount Sinai

An experimental monoclonal antibody, tulisokibart, shows promise in treating ulcerative colitis, inducing remission in 26.5% of patients compared to 1.5% in placebo group, according to a study in the New England Journal of Medicine. The treatment targets TL1A protein, reducing inflammation and fibrosis, and may offer a new therapeutic option for those unresponsive to other treatments.

A phase 2 trial of tulisokibart, a monoclonal antibody for moderate-to-severe ulcerative colitis, showed significant benefits in reducing inflammation and inducing remission in patients unresponsive to conventional IBD treatments. The study, led by Mount Sinai, will be published in The New England Journal of Medicine. Tulisokibart targets TL1A, a protein involved in UC inflammation, offering a new treatment option for patients with unmet needs in conventional therapies.

Tulisokibart, an investigational monoclonal antibody, showed higher clinical remission rates in patients with moderately to severely active ulcerative colitis compared to placebo in a phase II trial. 26% achieved remission with tulisokibart vs. 1% with placebo. The drug targets TL1A, a cytokine implicated in inflammatory bowel disease, offering a new therapeutic approach.

Drs. Lazarev and Sindhu critique vorasidenib, an FDA-approved brain tumor drug, questioning its approval process and benefits, highlighting ethical concerns and lack of clear survival or quality of life improvements compared to existing treatments.

Prediabetes in teens linked to higher risk of gestational diabetes, hypertensive disorders, and preterm delivery in later pregnancies, according to a study published in JAMA Network Open.

Nomic and PICI collaborate to profile ~3000 blood samples from RADIOHEAD study using nELISA™ to understand immunotherapy responses, aiming to improve patient care through precision medicine.

John P. Sfakianos, MD discussed a study on BCG resistance in bladder cancer using spatial transcriptomics and imaging mass cytometry, leading to the ENHANCE trial combining durvalumab and monalizumab in BCG-resistant NMIBC patients, funded by BCAN.

FDA approves ribociclib for HR+/HER2– breast cancer, AMG 193 shows activity in MTAP-deleted tumors, pembrolizumab plus chemo for mesothelioma, neoadjuvant pembrolizumab/chemo boosts OS in TNBC, and experts discuss 2024 IASLC World Conference on Lung Cancer findings.

Lung cancer experts discuss practice-changing research and new agents at the 2024 IASLC World Conference, highlighting Ivonescimab's potential in NSCLC, rethinking immunotherapy approaches, emerging biomarker-driven therapies, promising HER2 TKIs, ADC developments in SCLC, novel drug delivery platforms, and patient-centered care.